1. Home >
  2. M&A >
  3. Stake Purchase >
  4. United States >
  5. California >
  6. Illumina Invests In MyOme

Investment Summary

Illumina Invests In MyOme

On December 11, 2025, Illumina invested in life science company MyOme

Investment Highlights
  • This is Illumina’s 20th transaction in the Life Science sector.
  • This is Illumina’s 22nd transaction in the United States.
  • This is Illumina’s 12th transaction in California.

Investment Summary
Date 2025-12-11
Target MyOme
Sector Life Science
Investor(s) Illumina
Deal Type Stake Purchase

Target

MyOme

Palo Alto, California, United States
MyOme is a clinical whole-genome analysis platform company that provides genomic sequencing and analysis services to help individuals and healthcare providers understand genetic risk factors for inherited diseases, guide personalised health decisions, and support diagnostic evaluation. MyOme was founded in 2017 and is headquartered in Menlo Park, California.

Search 214,877 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Investor(S) 1

Investor

Illumina

San Diego, California, United States
Category Company
Founded 1998
Sector Life Science
Employees10,590
Revenue 4.4B USD (2024)
DESCRIPTION
Entrance to Illumina's corporate headquarters in San Diego, California.
Entrance to Illumina's corporate headquarters in San Diego, California.

Illumina is a developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. Illumina provides innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. Illumina was formed in 1998 and is based in San Diego, California.

DEAL STATS #
Overall 31 of 31
Sector: Life Science M&A 20 of 20
Type: Stake Purchase M&A Deals 14 of 14
State: California M&A 12 of 12
Country: United States M&A 22 of 22
Year: 2025 M&A 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2025-06-23 SomaLogic

Boulder, Colorado, United States

SomaLogic is a data-driven proteomics technology provides health-management information. SomaLogic was founded in 2000 and is based in Boulder, Colorado.

Buy $350M
Mergr

Solution for

Product

Company

Legal